全文获取类型
收费全文 | 13501篇 |
免费 | 1417篇 |
国内免费 | 28篇 |
专业分类
耳鼻咽喉 | 193篇 |
儿科学 | 397篇 |
妇产科学 | 319篇 |
基础医学 | 1805篇 |
口腔科学 | 422篇 |
临床医学 | 1463篇 |
内科学 | 2486篇 |
皮肤病学 | 120篇 |
神经病学 | 1108篇 |
特种医学 | 511篇 |
外国民族医学 | 1篇 |
外科学 | 2178篇 |
综合类 | 329篇 |
一般理论 | 19篇 |
预防医学 | 1445篇 |
眼科学 | 341篇 |
药学 | 930篇 |
中国医学 | 15篇 |
肿瘤学 | 864篇 |
出版年
2021年 | 177篇 |
2020年 | 129篇 |
2019年 | 218篇 |
2018年 | 254篇 |
2017年 | 209篇 |
2016年 | 205篇 |
2015年 | 246篇 |
2014年 | 296篇 |
2013年 | 468篇 |
2012年 | 612篇 |
2011年 | 622篇 |
2010年 | 411篇 |
2009年 | 367篇 |
2008年 | 595篇 |
2007年 | 622篇 |
2006年 | 566篇 |
2005年 | 587篇 |
2004年 | 611篇 |
2003年 | 605篇 |
2002年 | 547篇 |
2001年 | 389篇 |
2000年 | 396篇 |
1999年 | 360篇 |
1998年 | 177篇 |
1997年 | 177篇 |
1996年 | 127篇 |
1995年 | 124篇 |
1993年 | 127篇 |
1992年 | 252篇 |
1991年 | 249篇 |
1990年 | 266篇 |
1989年 | 236篇 |
1988年 | 220篇 |
1987年 | 178篇 |
1986年 | 237篇 |
1985年 | 193篇 |
1984年 | 162篇 |
1983年 | 165篇 |
1982年 | 124篇 |
1981年 | 113篇 |
1980年 | 138篇 |
1979年 | 164篇 |
1978年 | 142篇 |
1977年 | 138篇 |
1976年 | 111篇 |
1975年 | 137篇 |
1974年 | 144篇 |
1973年 | 146篇 |
1972年 | 111篇 |
1971年 | 110篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
E. Niclas Jonsson Rujia Xie Scott F. Marshall Rosalin H. Arends 《British journal of clinical pharmacology》2016,81(4):688-699
AimsThe aims were to 1) develop the pharmacokinetics model to describe and predict observed tanezumab concentrations over time, 2) test possible covariate parameter relationships that could influence clearance and distribution and 3) assess the impact of fixed dosing vs. a dosing regimen adjusted by body weight.MethodsIndividual concentration–time data were determined from 1608 patients in four phase 3 studies conducted to assess efficacy and safety of intravenous tanezumab. Patients received two or three intravenous doses (2.5, 5 or 10 mg) every 8 weeks. Blood samples for assessment of tanezumab PK were collected at baseline, 1 h post‐dose and at weeks 4, 8, 16 and 24 (or early termination) in all studies. Blood samples were collected at week 32 in two studies. Plasma samples were analyzed using a sensitive, specific, validated enzyme‐linked immunosorbent assay.ResultsA two compartment model with parallel linear and non‐linear elimination processes adequately described the data. Population estimates for clearance (CL), central volume (V
1), peripheral volume (V
2), inter‐compartmental clearance, maximum elimination capacity (VM) and concentration at half‐maximum elimination capacity were 0.135 l day–1, 2.71 l, 1.98 l, 0.371 l day–1, 8.03 μg day–1 and 27.7 ng ml–1, respectively. Inter‐individual variability (IIV) was included on CL, V
1, V
2 and VM. A mixture model accounted for the distribution of residual error. While gender, dose and creatinine clearance were significant covariates, only body weight as a covariate of CL, V
1 and V
2 significantly reduced IIV.ConclusionsThe small increase in variability associated with fixed dosing is consistent with other monoclonal antibodies and does not change risk : benefit. 相似文献
3.
4.
5.
6.
7.
Summary— KR31080 (2-butyl-5-methyl-6-(1-oxopyridin-2-yl)-3-[[2'-(1H-tetrazol-5-yl) biphenyl-4-yl]methyl]-3H-imidazo[4,5-b] pyridine) is a potent inhibitor of angiotensin type 1 (AT1 ) receptors in rabbit aorta and human recombinant AT1 receptors. In the isolated rabbit thoracic aorta, KR31080 caused a nonparallel shift to the right of the concentration-response curves to angiotensin II (All) with decreased maximal response (pD'2 = 10.1 ± 0.1), but had no effect on the contractile response induced by norepinephrine. KR31080 inhibited specific [125 I]AII binding to rabbit aortic membranes (AT, receptors) and [125 I][Sar1 , Ile8 ]AII binding to human recombinant AT1 receptors in a concentration-dependent manner with IC50 values of 0.84 ± 0.08 nM and 1.92 ± 0.15 nM, respectively, but did not inhibit specific [125 I)AII binding to bovine cerebellum membranes (ÀT2 receptors). In the Scatchard analysis, KR31080 interacted with rabbit aortic AT1 receptors in a competitive manner, similar to losartan. These results demonstrate that KR31080 is a potent and AT1 selective angiotensin receptor antagonist which exerts a competitive antagonism in the [125 I]AII binding assay and insurmountable AT1 receptor antagonism in the functional study. 相似文献
8.
9.
10.
Venom from the scorpion Pandinus imperator potently and selectively blocks voltage-gated K+ channels in bullfrog neurones (Pappone, P. A. and Cahalan, M. D. 1987, J. Neurosci. 7, 3300-3305). Its effects on neuromuscular transmission have now been assessed. Twitch tension studies on chick biventer cervicis preparations showed that the venom (1 microgram/ml and above) significantly augmented responses to nerve but not muscle stimulation; there was little change in postjunctional sensitivity to cholinoceptor agonists or K+-induced depolarization. Electrophysiological studies on mouse triangularis sterni preparations revealed that the venom had no effect on spontaneous transmitter release, but increased evoked transmitter release. Extracellular recordings of nerve terminal action potentials showed that the venom selectively reduced the component of the waveform associated with K+ currents. These results confirm that this venom can selectively block neuronal K+ currents, and they show that this can facilitate the release of acetylcholine at the neuromuscular junction. 相似文献